What is the brand name of the levodopa‑carbidopa intestinal gel infusion system used for Parkinson's disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Levodopa-Carbidopa Intestinal Gel Infusion System

The brand name of the levodopa-carbidopa intestinal gel infusion system for Parkinson's disease is DUOPA (marketed by AbbVie). 1

Product Details

DUOPA is the FDA-approved brand name for carbidopa and levodopa enteral suspension delivered via continuous intrajejunal infusion. The formulation contains 4.63 mg/mL of carbidopa (anhydrous) and 20 mg/mL of levodopa 1.

Delivery System Components

The therapy utilizes:

  • CADD-Legacy pump (manufactured by Smiths Medical ASD, Inc.) for continuous delivery 1
  • Percutaneous endoscopic gastrostomy with jejunal tube (PEG-J) placement
  • Medication cassette reservoirs (100 mL capacity) 1

Alternative Terminology

In clinical literature and international markets, this same therapy is also referred to as:

  • LCIG (levodopa-carbidopa intestinal gel) 2
  • Duodopa (the European brand name, also by Abbott/AbbVie) 3, 4, 5, 6

Recent Development

A newer formulation called LECIG (levodopa-entacapone-carbidopa intestinal gel) has been approved in Europe, which adds entacapone to enhance levodopa bioavailability 7, 8. This represents an evolution of the original DUOPA/Duodopa formulation.

Evidence Base

DUOPA/LCIG has Level 2 evidence supporting its use in advanced Parkinson's disease with motor fluctuations, based on 2 randomized controlled trials 2. The 2024 European Academy of Neurology/Movement Disorder Society guidelines rank it third in evidence strength among invasive therapies for Parkinson's disease, after subthalamic nucleus deep brain stimulation and globus pallidus interna stimulation 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.